Bole Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bole Tian has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Kang Xue
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
11 shared publicationsXing Huang
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
11 shared publicationsZihe Wang
11 shared publicationsLi Wang
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
10 shared publications- Junjie Xiong
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
9 shared publications Xiaofeng Liu
8 shared publications
Latest Publications
- 16 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF15
Radiotherapy Combined with Serplulimab and Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Multicenter, Single-Arm, Phase II Trial
Purpose: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel (GnP), and radiotherapy (ICSBR regimen) as first-line treatment for patients with mPDAC (ChiCTR2300073237). Patients and Methods: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and GnP administered in 21-day cycles, combined with stereotactic body radiotherapy (SBRT) directed at the primary or metastatic sites during cycle 2. Additionally, a comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. Results: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% [95% confidence interval (CI), 67.2%–91.1%]. The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3–12 months) and 14 months [95% CI, 12 months–not reached (NR)], respectively. The objective response rate (ORR) was 73.9% (95% CI, 58.9%–85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline circulating tumor DNA (ctDNA) negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein (FAP)–positive cancer-associated fibroblast (CAF) and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. Conclusions: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.
- 16 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF15
Radiotherapy Combined with Serplulimab and Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Multicenter, Single-Arm, Phase II Trial
Purpose: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel (GnP), and radiotherapy (ICSBR regimen) as first-line treatment for patients with mPDAC (ChiCTR2300073237). Patients and Methods: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and GnP administered in 21-day cycles, combined with stereotactic body radiotherapy (SBRT) directed at the primary or metastatic sites during cycle 2. Additionally, a comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. Results: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% [95% confidence interval (CI), 67.2%–91.1%]. The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3–12 months) and 14 months [95% CI, 12 months–not reached (NR)], respectively. The objective response rate (ORR) was 73.9% (95% CI, 58.9%–85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline circulating tumor DNA (ctDNA) negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein (FAP)–positive cancer-associated fibroblast (CAF) and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. Conclusions: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.
- 20 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-19
Analysis of the Safety and Efficacy of Cryoablation in Patients with Locally Advanced Pancreatic Cancer
Cryoablation is emerging as a potential treatment option for locally advanced pancreatic cancer (LAPC). The aim of this study was to retrospectively evalua
- 20 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-19
Analysis of the Safety and Efficacy of Cryoablation in Patients with Locally Advanced Pancreatic Cancer
Cryoablation is emerging as a potential treatment option for locally advanced pancreatic cancer (LAPC). The aim of this study was to retrospectively evalua
- 12 June 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (8) , 111952
Association of multidisciplinary team management with clinical outcomes in hepatobiliary and pancreatic malignancies: A systematic review and meta-analysis
- 12 June 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (8) , 111952
Association of multidisciplinary team management with clinical outcomes in hepatobiliary and pancreatic malignancies: A systematic review and meta-analysis
- 27 May 2026
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 301 (1) , 126
Targeting KIF18B overcomes oxaliplatin resistance in esophageal squamous cell carcinoma via suppression of the ATR/CHK1 axis
Esophageal squamous cell carcinoma (ESCC) is aggressive with poor prognosis, frequently driven by chemotherapy resistance. Kinesin family member 18B (KIF18B) is implicated in tumor progression, but its role in ESCC chemoresistance remains unclear. To investigate KIF18B’s clinical relevance and mechanistic contribution to oxaliplatin resistance in ESCC, KIF18B expression was analyzed in TCGA data, ESCC cell lines/tissues (qPCR, Western blot, IHC), and correlated with survival (Kaplan-Meier). Results showed that, KIF18B was significantly elevated in ESCC and correlated with shorter overall/progression-free survival. Knockdown reversed oxaliplatin resistance, reducing IC50 from 8.5 µM to 3 µM, restoring apoptosis, and inducing G2/M arrest. Silencing suppressed the ATR/CHK1 pathway (reduced p-ATR, p-CHK1, WEE1, CDC25A) and increased γH2AX foci. Co-IP confirmed KIF18B-ATR interaction, suggesting stabilization of DNA damage signaling. In vivo, KIF18B knockdown synergized with oxaliplatin, achieving > 80% tumor suppression and reduced Ki-67/p-ATR/p-CHK1 levels. In conclusion, KIF18B is a prognostic biomarker and therapeutic target in ESCC. Its inhibition overcomes oxaliplatin resistance by disrupting KIF18B-ATR interaction and ATR/CHK1-mediated DNA repair. Combining KIF18B targeting with chemotherapy or ATR inhibitors represents a promising strategy for refractory ESCC.
- 27 May 2026
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 301 (1) , 126
Targeting KIF18B overcomes oxaliplatin resistance in esophageal squamous cell carcinoma via suppression of the ATR/CHK1 axis
Esophageal squamous cell carcinoma (ESCC) is aggressive with poor prognosis, frequently driven by chemotherapy resistance. Kinesin family member 18B (KIF18B) is implicated in tumor progression, but its role in ESCC chemoresistance remains unclear. To investigate KIF18B’s clinical relevance and mechanistic contribution to oxaliplatin resistance in ESCC, KIF18B expression was analyzed in TCGA data, ESCC cell lines/tissues (qPCR, Western blot, IHC), and correlated with survival (Kaplan-Meier). Results showed that, KIF18B was significantly elevated in ESCC and correlated with shorter overall/progression-free survival. Knockdown reversed oxaliplatin resistance, reducing IC50 from 8.5 µM to 3 µM, restoring apoptosis, and inducing G2/M arrest. Silencing suppressed the ATR/CHK1 pathway (reduced p-ATR, p-CHK1, WEE1, CDC25A) and increased γH2AX foci. Co-IP confirmed KIF18B-ATR interaction, suggesting stabilization of DNA damage signaling. In vivo, KIF18B knockdown synergized with oxaliplatin, achieving > 80% tumor suppression and reduced Ki-67/p-ATR/p-CHK1 levels. In conclusion, KIF18B is a prognostic biomarker and therapeutic target in ESCC. Its inhibition overcomes oxaliplatin resistance by disrupting KIF18B-ATR interaction and ATR/CHK1-mediated DNA repair. Combining KIF18B targeting with chemotherapy or ATR inhibitors represents a promising strategy for refractory ESCC.
- Open Access
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3543
Safety and Efficiency of Various Pancreatic Enucleation Procedures: A Systematic Review and Meta-Analysis
Objective: This study aimed to systematically compare the short-term outcomes of minimally invasive pancreatic enucleation (MI-pEn), including laparoscopic and robotic-assisted approaches, and open pancreatic enucleation (O-pEn). Methods: A systematic search of PubMed, MEDLINE, Embase, and Web of Science was conducted for studies published between January 1990 and December 2025 that compared various types of pancreatic enucleation. The literature screening, data extraction, and quality assessment followed the PRISMA guidelines. The meta-analysis was performed using RevMan 5.4.1 and R 4.3.0. Results: Fifteen studies were included, with thirteen comparative studies (463 MI-pEn, 547 O-pEn) incorporated into the meta-analysis. Two studies comparing laparoscopic and robot-assisted enucleation were also included. No significant difference in clinically relevant postoperative pancreatic fistula (CR-POPF) was detected between MI-pEn and O-pEn (OR = 0.78; 95% CI: 0.56–1.07; p = 0.12). However, MI-pEn was associated with significantly reduced operation time (MD = −21.24; p = 0.01), blood loss (MD = −75.88; p < 0.00001), hospital stay (MD = −2.07; p = 0.001), and wound infection (OR = 0.3; p = 0.03). Direct comparisons between robotic and laparoscopic enucleation revealed no significant differences in any outcomes. Conclusions: MI-pEn is safe and feasible and offers advantages in terms of operative time, blood loss, and recovery without increasing complications. Robotic and laparoscopic approaches yield comparable short-term outcomes in pancreatic enucleation, although the potential advantage of robotic surgery in reducing pancreatic fistula risk warrants further validation.
- 6 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3543
Open AccessSafety and Efficiency of Various Pancreatic Enucleation Procedures: A Systematic Review and Meta-Analysis
Objective: This study aimed to systematically compare the short-term outcomes of minimally invasive pancreatic enucleation (MI-pEn), including laparoscopic and robotic-assisted approaches, and open pancreatic enucleation (O-pEn). Methods: A systematic search of PubMed, MEDLINE, Embase, and Web of Science was conducted for studies published between January 1990 and December 2025 that compared various types of pancreatic enucleation. The literature screening, data extraction, and quality assessment followed the PRISMA guidelines. The meta-analysis was performed using RevMan 5.4.1 and R 4.3.0. Results: Fifteen studies were included, with thirteen comparative studies (463 MI-pEn, 547 O-pEn) incorporated into the meta-analysis. Two studies comparing laparoscopic and robot-assisted enucleation were also included. No significant difference in clinically relevant postoperative pancreatic fistula (CR-POPF) was detected between MI-pEn and O-pEn (OR = 0.78; 95% CI: 0.56–1.07; p = 0.12). However, MI-pEn was associated with significantly reduced operation time (MD = −21.24; p = 0.01), blood loss (MD = −75.88; p < 0.00001), hospital stay (MD = −2.07; p = 0.001), and wound infection (OR = 0.3; p = 0.03). Direct comparisons between robotic and laparoscopic enucleation revealed no significant differences in any outcomes. Conclusions: MI-pEn is safe and feasible and offers advantages in terms of operative time, blood loss, and recovery without increasing complications. Robotic and laparoscopic approaches yield comparable short-term outcomes in pancreatic enucleation, although the potential advantage of robotic surgery in reducing pancreatic fistula risk warrants further validation.
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (5) , 131
Construction of a predictive model for postoperative pancreatic fistula following pancreaticoduodenectomy and an exploration of inflammatory biomarker associations
Background: Clinically relevant postoperative pancreatic fistula (CR-POPF) remains a significant cause of morbidity after pancreaticoduodenectomy (PD). Existing predictive tools, such as the Fistula risk score (FRS), demonstrate inconsistent performance. This study aimed to develop a nomogram with superior predictive accuracy for CR-POPF. Methods: This retrospective cohort study analysed 1,026 PD patients (70% training, 30% validation). Least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression were used to identify independent predictors and construct a dynamic nomogram. Model performance was assessed via the area under the curve (AUC), calibration, and decision curve analysis (DCA). Results: CR-POPF occurred in 18.4% of the cohort. Multivariable analysis identified five independent predictors: soft pancreatic texture, small pancreatic duct diameter, elevated body mass index (BMI), prolonged operation time, and absence of diabetes mellitus. Inflammatory markers were not retained in the final model. The nomogram showed robust discrimination with AUCs of 0.770 (training) and 0.759 (validation), significantly outperforming both the alternative FRS (a-FRS) (AUC =0.579) and the traditional FRS (AUC =0.529). Conclusions: We successfully developed and internally validated a superior nomogram integrating anatomical, metabolic, and procedural factors. This highly accurate tool facilitates precise preoperative and intraoperative risk stratification, guiding tailored preventive strategies to mitigate the burden of POPF.
- 1 May 2026
- Published by AME Publishing Company in Gland Surgery
- Vol. 15 (5) , 131
Open AccessConstruction of a predictive model for postoperative pancreatic fistula following pancreaticoduodenectomy and an exploration of inflammatory biomarker associations
Background: Clinically relevant postoperative pancreatic fistula (CR-POPF) remains a significant cause of morbidity after pancreaticoduodenectomy (PD). Existing predictive tools, such as the Fistula risk score (FRS), demonstrate inconsistent performance. This study aimed to develop a nomogram with superior predictive accuracy for CR-POPF. Methods: This retrospective cohort study analysed 1,026 PD patients (70% training, 30% validation). Least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression were used to identify independent predictors and construct a dynamic nomogram. Model performance was assessed via the area under the curve (AUC), calibration, and decision curve analysis (DCA). Results: CR-POPF occurred in 18.4% of the cohort. Multivariable analysis identified five independent predictors: soft pancreatic texture, small pancreatic duct diameter, elevated body mass index (BMI), prolonged operation time, and absence of diabetes mellitus. Inflammatory markers were not retained in the final model. The nomogram showed robust discrimination with AUCs of 0.770 (training) and 0.759 (validation), significantly outperforming both the alternative FRS (a-FRS) (AUC =0.579) and the traditional FRS (AUC =0.529). Conclusions: We successfully developed and internally validated a superior nomogram integrating anatomical, metabolic, and procedural factors. This highly accurate tool facilitates precise preoperative and intraoperative risk stratification, guiding tailored preventive strategies to mitigate the burden of POPF.
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (11) , 2213-2226
A retrospective cohort study on the differential overall survival rates between surgical intervention and chemotherapy in stage IV pancreatic cancer patients
Background: Patients with pancreatic cancer and liver metastases (PCLM) are typically deemed ineligible for curative surgery, with chemotherapy being the standard care. However, surgical resection may benefit select patients. This study investigated whether integrating surgery with chemotherapy improves overall survival (OS) compared to chemotherapy alone in PCLM. Methods: We conducted a retrospective cohort study of 24,802 patients with stage IV pancreatic cancer from the the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program (2000–2021). A 1:4 propensity score matching (PSM) was applied to balance 15 baseline covariates. Survival differences between groups were assessed via Kaplan-Meier and multivariate Cox analyses. Results: A total of 24,802 patients were included in this study, constituting a cohort with a biased distribution of age, sex, and disease stage. Among them, only 686 (2.8%) underwent surgery combined with chemotherapy, while 24,116 (97.2%) received chemotherapy alone. Univariate analysis revealed that patients younger than 65 years of age presented a reduced risk of mortality [hazard ratio (HR) =1.3]. Similarly, an earlier disease stage and a lower burden of metastatic disease were associated with a more favorable prognosis. According to the multivariate Cox proportional hazards model, primary tumor location emerged as an independent predictor of survival. Specifically, patients with tumors in the pancreatic body (HR =0.5) or tail (HR =0.4) demonstrated a significantly lower mortality risk than did those with tumors in the pancreatic head. Furthermore, Kaplan-Meier analysis indicated that patients who underwent surgery combined with chemotherapy had a substantially prolonged survival duration relative to those receiving chemotherapy alone (median OS: 18 vs. 6 months; Pvs. 8 months, PConclusions: In this retrospective analysis, selected patients receiving surgery plus chemotherapy showed significantly longer OS than those receiving chemotherapy alone. However, the attenuation of survival benefit after PSM and residual imbalances in key prognostic factors suggest that the observed advantage may largely reflect patient selection rather than a true treatment effect. Prospective studies with detailed data on performance status and metastatic burden are warranted to define the role of surgery in this setting.
- 1 November 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (11) , 2213-2226
Open AccessA retrospective cohort study on the differential overall survival rates between surgical intervention and chemotherapy in stage IV pancreatic cancer patients
Background: Patients with pancreatic cancer and liver metastases (PCLM) are typically deemed ineligible for curative surgery, with chemotherapy being the standard care. However, surgical resection may benefit select patients. This study investigated whether integrating surgery with chemotherapy improves overall survival (OS) compared to chemotherapy alone in PCLM. Methods: We conducted a retrospective cohort study of 24,802 patients with stage IV pancreatic cancer from the the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program (2000–2021). A 1:4 propensity score matching (PSM) was applied to balance 15 baseline covariates. Survival differences between groups were assessed via Kaplan-Meier and multivariate Cox analyses. Results: A total of 24,802 patients were included in this study, constituting a cohort with a biased distribution of age, sex, and disease stage. Among them, only 686 (2.8%) underwent surgery combined with chemotherapy, while 24,116 (97.2%) received chemotherapy alone. Univariate analysis revealed that patients younger than 65 years of age presented a reduced risk of mortality [hazard ratio (HR) =1.3]. Similarly, an earlier disease stage and a lower burden of metastatic disease were associated with a more favorable prognosis. According to the multivariate Cox proportional hazards model, primary tumor location emerged as an independent predictor of survival. Specifically, patients with tumors in the pancreatic body (HR =0.5) or tail (HR =0.4) demonstrated a significantly lower mortality risk than did those with tumors in the pancreatic head. Furthermore, Kaplan-Meier analysis indicated that patients who underwent surgery combined with chemotherapy had a substantially prolonged survival duration relative to those receiving chemotherapy alone (median OS: 18 vs. 6 months; Pvs. 8 months, PConclusions: In this retrospective analysis, selected patients receiving surgery plus chemotherapy showed significantly longer OS than those receiving chemotherapy alone. However, the attenuation of survival benefit after PSM and residual imbalances in key prognostic factors suggest that the observed advantage may largely reflect patient selection rather than a true treatment effect. Prospective studies with detailed data on performance status and metastatic burden are warranted to define the role of surgery in this setting.
- 1 October 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1142-1148
Modified TNM staging system for well-differentiated pancreatic neuroendocrine tumors: A comparative study with the AJCC 9th edition
- 1 October 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1142-1148
Modified TNM staging system for well-differentiated pancreatic neuroendocrine tumors: A comparative study with the AJCC 9th edition